1	Un	Un		C0205447_1	calificador_1	0-2	160_QUEST_clinical_caseMIR	SENT1	-	-
2	paciente	paciente	NCCS000	C0030705	persona	3-11	160_QUEST_clinical_caseMIR	SENT1	-	-
3	de	de	SPS00	C0332285	atributo	12-14	160_QUEST_clinical_caseMIR	SENT1	-	-
4	56	56		-	-	15-17	160_QUEST_clinical_caseMIR	SENT1	-	-
5	años	año	NCMP000	C0439234	calificador	18-22	160_QUEST_clinical_caseMIR	SENT1	-	-
6	de	de	SPS00	C0001779_1	entidad_observable_1	23-25	160_QUEST_clinical_caseMIR	SENT1	-	-
7	edad	edad	NCFS000	C0001779_2	entidad_observable_2	26-30	160_QUEST_clinical_caseMIR	SENT1	-	-
8	va	ir	VMIP3S0	-	-	31-33	160_QUEST_clinical_caseMIR	SENT1	-	-
9	a	a	SPS00	-	-	34-35	160_QUEST_clinical_caseMIR	SENT1	-	-
10	ser	ser	VSN0000	-	-	36-39	160_QUEST_clinical_caseMIR	SENT1	-	-
11	intervenido	intervenir	VMP00SM	-	-	40-51	160_QUEST_clinical_caseMIR	SENT1	-	-
12	por	por	SPS00	C0678226	atributo	52-55	160_QUEST_clinical_caseMIR	SENT1	-	-
13	un	un		C0205447_1	calificador_1	56-58	160_QUEST_clinical_caseMIR	SENT1	-	-
14	cáncer	cáncer	NCMS000	C1306459#C0936282#C0006826	anomalía_morfológica#trastorno	59-65	160_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
15	de	de	SPS00	C0521255_1	procedimiento_1	66-68	160_QUEST_clinical_caseMIR	SENT1	-	-
16	esófago	esófago	NCMS000	C0521255_2	procedimiento_2	69-76	160_QUEST_clinical_caseMIR	SENT1	B-Estructura_Corporal	-
17	en	en	SPS00	C1720294#C0332285	calificador#atributo	77-79	160_QUEST_clinical_caseMIR	SENT1	-	-
18	las	el	DA0FP0	-	-	80-83	160_QUEST_clinical_caseMIR	SENT1	-	-
19	próximas	próximo	AQ0FP0	-	-	84-92	160_QUEST_clinical_caseMIR	SENT1	-	-
20	cuatro	cuatro		-	-	93-99	160_QUEST_clinical_caseMIR	SENT1	-	-
21	semanas	semana	NCFP000	C0439230	calificador	100-107	160_QUEST_clinical_caseMIR	SENT1	-	-
22	.	.	Fp	-	-	107-108	160_QUEST_clinical_caseMIR	SENT1	-	-

1	Entre	entre	SPS00	C0205103	calificador	109-114	160_QUEST_clinical_caseMIR	SENT2	-	-
2	sus	su	DP3CP0	-	-	115-118	160_QUEST_clinical_caseMIR	SENT2	-	-
3	antecedentes	antecedente	NCMP000	-	-	119-131	160_QUEST_clinical_caseMIR	SENT2	-	-
4	personales	personal	AQ0CP0	-	-	132-142	160_QUEST_clinical_caseMIR	SENT2	-	-
5	destaca	destacar	VMIP3S0	-	-	143-150	160_QUEST_clinical_caseMIR	SENT2	-	-
6	una	una		C0205447_1	calificador_1	151-154	160_QUEST_clinical_caseMIR	SENT2	-	-
7	cardiopatía	cardiopatía	NCFS000	C0002962#C0151744_1	trastorno_1	155-166	160_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
8	isquémica	isquémico	AQ0FS0	C0002962#C0151744_2	trastorno_2	167-176	160_QUEST_clinical_caseMIR	SENT2	B-Calificador	-
9	que	que	PR0CN000	-	-	177-180	160_QUEST_clinical_caseMIR	SENT2	-	-
10	precisó	precisar	VMIS3S0	-	-	181-188	160_QUEST_clinical_caseMIR	SENT2	-	-
11	de	de	SPS00	C0332285	atributo	189-191	160_QUEST_clinical_caseMIR	SENT2	-	-
12	la	el	DA0FS0	-	-	192-194	160_QUEST_clinical_caseMIR	SENT2	-	-
13	implantación	implantación	NCFS000	-	-	195-207	160_QUEST_clinical_caseMIR	SENT2	-	-
14	,	,	Fc	-	-	207-208	160_QUEST_clinical_caseMIR	SENT2	-	-
15	11	11		-	-	209-211	160_QUEST_clinical_caseMIR	SENT2	-	-
16	meses	mes	NCMP000	C0439231	calificador	212-217	160_QUEST_clinical_caseMIR	SENT2	-	-
17	antes	antes	RG	C0332152	atributo	218-223	160_QUEST_clinical_caseMIR	SENT2	-	-
18	,	,	Fc	-	-	223-224	160_QUEST_clinical_caseMIR	SENT2	-	-
19	de	de	SPS00	C0332285	atributo	225-227	160_QUEST_clinical_caseMIR	SENT2	-	-
20	4	4		-	-	228-229	160_QUEST_clinical_caseMIR	SENT2	-	-
21	endoprótesis	endoprótesis	NCFN000	-	-	230-242	160_QUEST_clinical_caseMIR	SENT2	-	-
22	coronarias	coronario	AQ0FP0	-	-	243-253	160_QUEST_clinical_caseMIR	SENT2	B-Estructura_Corporal	-
23	(	(	Fpa	-	-	254-255	160_QUEST_clinical_caseMIR	SENT2	-	-
24	"	"	Fe	-	-	255-256	160_QUEST_clinical_caseMIR	SENT2	-	-
25	stents	stents	NCMP000	-	-	256-262	160_QUEST_clinical_caseMIR	SENT2	-	-
26	"	"	Fe	-	-	262-263	160_QUEST_clinical_caseMIR	SENT2	-	-
27	)	)	Fpt	-	-	263-264	160_QUEST_clinical_caseMIR	SENT2	-	-
28	recubiertas	recubrir	VMP00PF	-	-	265-276	160_QUEST_clinical_caseMIR	SENT2	-	-
29	con	con	SPS00	C0332287	atributo	277-280	160_QUEST_clinical_caseMIR	SENT2	-	-
30	fármacos	fármaco	NCMP000	C0013227	sustancia	281-289	160_QUEST_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
31	.	.	Fp	-	-	289-290	160_QUEST_clinical_caseMIR	SENT2	-	-

1	Por	por	SPS00	C0678226	atributo	291-294	160_QUEST_clinical_caseMIR	SENT3	-	-
2	ese	ese	DD0MS0	-	-	295-298	160_QUEST_clinical_caseMIR	SENT3	-	-
3	motivo	motivo	NCMS000	-	-	299-305	160_QUEST_clinical_caseMIR	SENT3	-	-
4	se	se	P00CN000	-	-	306-308	160_QUEST_clinical_caseMIR	SENT3	-	-
5	encuentra	encontrar	VMIP3S0	-	-	309-318	160_QUEST_clinical_caseMIR	SENT3	-	-
6	en	en	SPS00	C1720294#C0332285	calificador#atributo	319-321	160_QUEST_clinical_caseMIR	SENT3	-	-
7	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	322-333	160_QUEST_clinical_caseMIR	SENT3	-	-
8	con	con	SPS00	C0332287	atributo	334-337	160_QUEST_clinical_caseMIR	SENT3	-	-
9	doble	doble	AQ0CS0	C0205173	calificador	338-343	160_QUEST_clinical_caseMIR	SENT3	-	-
10	antiagregación	antiagregación	NCFS000	-	-	344-358	160_QUEST_clinical_caseMIR	SENT3	-	-
11	plaquetaria	plaquetario	AQ0FS0	-	-	359-370	160_QUEST_clinical_caseMIR	SENT3	-	-
12	con	con	SPS00	C0332287	atributo	371-374	160_QUEST_clinical_caseMIR	SENT3	-	-
13	100	100	Z	-	-	375-378	160_QUEST_clinical_caseMIR	SENT3	-	-
14	mg	mg	NCMN000	-	-	379-381	160_QUEST_clinical_caseMIR	SENT3	-	-
15	de	de	SPS00	C0332285	atributo	382-384	160_QUEST_clinical_caseMIR	SENT3	-	-
16	ácido	ácido	NCMS000	C0004057_1	sustancia_1	385-390	160_QUEST_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
17	acetilsalicílico	acetilsalicílico	AQ0MS0	C0004057_2	sustancia_2	391-407	160_QUEST_clinical_caseMIR	SENT3	I-Grp_Medicamento	-
18	y	y	CC	C1706368	calificador	408-409	160_QUEST_clinical_caseMIR	SENT3	-	-
19	75	75	Z	-	-	410-412	160_QUEST_clinical_caseMIR	SENT3	-	-
20	mg	mg	NCMN000	-	-	413-415	160_QUEST_clinical_caseMIR	SENT3	-	-
21	de	de	SPS00	C0332285	atributo	416-418	160_QUEST_clinical_caseMIR	SENT3	-	-
22	clopidogrel	clopidogrel	NC00SC0	C0070166	producto#sustancia	419-430	160_QUEST_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
23	al	al	SP+DA	-	-	431-433	160_QUEST_clinical_caseMIR	SENT3	-	-
24	día	día	NCMS000	C0439228#C0332169	calificador	434-437	160_QUEST_clinical_caseMIR	SENT3	-	-
25	.	.	Fp	-	-	437-438	160_QUEST_clinical_caseMIR	SENT3	-	-

1	Qué	qué	DE0CN0	-	-	439-442	160_QUEST_clinical_caseMIR	SENT4	-	-
2	decisión	decisión	NCFS000	-	-	443-451	160_QUEST_clinical_caseMIR	SENT4	-	-
3	se	se	P00CN000	-	-	452-454	160_QUEST_clinical_caseMIR	SENT4	-	-
4	debería	deber	VMIC3S0	-	-	455-462	160_QUEST_clinical_caseMIR	SENT4	-	-
5	tomar	tomar	VMN0000	C1515187	calificador	463-468	160_QUEST_clinical_caseMIR	SENT4	-	-
6	sobre	sobre	SPS00	C1720294#C0205136	calificador	469-474	160_QUEST_clinical_caseMIR	SENT4	-	-
7	la	el	DA0FS0	-	-	475-477	160_QUEST_clinical_caseMIR	SENT4	-	-
8	antiagregación	antiagregación	NCFS000	-	-	478-492	160_QUEST_clinical_caseMIR	SENT4	-	-
9	preoperatoria	preoperatorio	AQ0FS0	C0445204	calificador	493-506	160_QUEST_clinical_caseMIR	SENT4	-	-
10	del	del	SP+DA	-	-	507-510	160_QUEST_clinical_caseMIR	SENT4	-	-
11	paciente	paciente	NCCS000	C0030705	persona	511-519	160_QUEST_clinical_caseMIR	SENT4	-	-
12	.	.	Fp	-	-	519-520	160_QUEST_clinical_caseMIR	SENT4	-	-

